ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anvatabart opadotin

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageARX788: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 18, 20214 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only31 open or runningphase 2since Mar 18, 2021Aug 14, 2017Dec 2026phase 2 · NCT04829604
Zhejiang Medicine10 open or runningphase 1since Jun 22, 2015Jun 22, 2015none ahead
  • Named in Johnson & Johnson’s own pipeline as JNJ-0683 (ARX788), phase 2, as of Oct 13, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zhejiang Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2015First study: phase 1 study in Breast NeoplasmsFirst studyNCT02512237 · 9 enrolled · Australia, New Zealand
  2. Jul 21, 2022Named anvatabart opadotinINNProposed as its International Nonproprietary Name in WHO's List 127 · before, ARX788

TargetBeta

“An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMA…”NCIt, read by Claude

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

The one study Zhejiang Medicine leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02512237Breast Neoplasms · Australia, New Zealand1TerminatedJan 20179

How it is read

Names in the registry

  • “ARX788”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.